Evidence map›Paper›PMID 40355842›Full record

ArticleBMC urology2025

Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort.

Aldéric Fraslin, Florian Colrat, Maryam Karimi, Julia Bonastre, Karine Groussard, Siguroli Teitsson, Alexis Prudent, Sébastien Branchoux, François Radvanyi, Simone Benhamou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aldéric FraslinBureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Florian ColratHealth Economics and Outcomes Research, Bristol Myers Squibb, Rueil-Malmaison, France. florian.colrat@bms.com.
Maryam KarimiBureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Julia BonastreBureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Karine GroussardINSERM, Paris, France.
Siguroli TeitssonHealth Economics and Outcomes Research, Bristol Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK.
Alexis PrudentMedical Affairs Department, Bristol Myers Squibb, Rueil-Malmaison, France.
Sébastien BranchouxHealth Economics and Outcomes Research, Bristol Myers Squibb, Rueil-Malmaison, France.
François RadvanyiUMR 144 CNRS, Institut Curie, Paris, France.
Simone BenhamouBureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Yves AlloryUMR 144 CNRS, Institut Curie, Paris, France.
Thierry LebretDepartment of Urology, Hôpital Foch, Suresnes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe characteristics, management, disease-free survival and overall survival of patients with muscle-invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR) undergoing radical cystectomy in France and a subgroup of these patients who did not receive adjuvant chemotherapy after RC and were managed with active surveillance only (MIBC-HR-ASO).

methodsPatients aged ≥ 18 years with MIBC who had radical cystectomy from October 2012 to June 2018 were identified in the prospective COBLAnCE bladder cancer cohort. Patients with metastatic disease were excluded. Patients were classified as MIBC-HR based on TNM staging. Disease-free and overall survival were estimated using the Kaplan-Meier method with their 95% confidence intervals (95%CI).

results256 patients with MIBC-HR were enrolled. The median age at diagnosis was 68.5 years and 204 patients were men (79.7%). 201 patients (78.5%) were current or former smokers. For staging, 226 patients were (y)pT3a or higher (88.3%) and 132 were N- (51.6%). Forty-six patients received neoadjuvant chemotherapy (18.0%), and 69 received adjuvant chemotherapy (27.0%). Of the patients receiving adjuvant chemotherapy only, 59 received cisplatin-based therapy (86.8%). 182 patients (71.1%) constituted the ASO subgroup. 175 patients (68.3%) experienced an event up to the end of follow-up. Median follow-up was 5.0 years. Median disease-free survival was 1.30 years [95%CI: 1.01-1.60] in the MIBC-HR cohort and 1.21 years [95%CI: 0.70-1.53] in the MIBC-HR-ASO subgroup. Median overall survival was 2.31 years [95%CI: 1.85-3.10] in the MIBC-HR cohort and 2.11 years [95%CI: 1.61-2.65] in the MIBC-HR-ASO subgroup. At 5 years, DFS was 27.4% [21.7;33.9%] in the MIBC-HR population and 23.7% [17.4;31.4] in the MIBC-HR-ASO population. OS at five years was 33.2% [27.1;40.0] for the MIBC-HR population and 29.6% [22.7;37.7] for the MIBC-HR-ASO population.

conclusionUsing real-world data, this study underscores the challenging prognosis of patients with MIBC-HR managed with RC, regardless of whether they receive adjuvant chemotherapy. New treatment protocols, such as the use of immunotherapies, may improve OS in this type of cancer, especially in the current therapeutic landscape where no highly effective treatment exists.

Indexed as

Neoplasm Recurrence, LocalUrinary Bladder NeoplasmsAgedAged, 80 and overChemotherapy, AdjuvantCohort StudiesCystectomyFemaleFranceHumansMaleMiddle AgedNeoplasm InvasivenessProspective StudiesSurvival RateTreatment OutcomeAdjuvant chemotherapyBladder cancerMuscle-invasive urothelial carcinomaProspective cohortRadical cystectomySurvival

Identifiers

PMID40355842
PMCPMC12067709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.